Bulletin
Investor Alert

Regeneron Pharmaceuticals Inc.

NAS: REGN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 26, 2022, 7:22 p.m.

/zigman2/quotes/203149337/composite

$

683.50

Change

+0.06 +0.0088%

Volume

Volume 28,085

Quotes are delayed by 20 min

/zigman2/quotes/203149337/composite

Today's close

$ 690.88

$ 683.44

Change

-7.44 -1.08%

Day low

Day high

$682.90

$697.01

Open

52 week low

52 week high

$492.13

$747.42

Open

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accel...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Valuation

P/E Current

9.60

P/E Ratio (with extraordinary items)

9.85

P/E Ratio (without extraordinary items)

8.77

Price to Sales Ratio

4.41

Price to Book Ratio

3.66

Price to Cash Flow Ratio

10.01

Enterprise Value to EBITDA

7.90

Enterprise Value to Sales

4.42

Efficiency

Total Asset Turnover

0.75

Liquidity

Current Ratio

3.56

Quick Ratio

3.07

Cash Ratio

1.45

Profitability

Gross Margin

83.05

Operating Margin

55.67

Pretax Margin

58.03

Net Margin

50.25

Return on Assets

37.91

Return on Equity

54.21

Return on Total Capital

50.85

Capital Structure

Total Debt to Total Assets

10.61

Officers and Executives

Name Age Officer Since Title
Dr. P. Roy Vagelos 90 1995 Chairman
Dr. Leonard S. Schleifer 68 1988 Co-President, Chief Executive Officer & Director
Dr. George Damis Yancopoulos 59 1989 Co-President, Director & Chief Scientific Officer
Ms. Patrice Gilooly - 1998 Senior VP-Quality Assurance & Operations
Mr. Robert E. Landry 55 2013 Chief Financial Officer & Executive VP-Finance

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/17/2022 Andrew J. Murphy
EVP Research
57   Disposition at $670.49 per share. 38,217
05/17/2022 Andrew J. Murphy
EVP Research
153   Disposition at $669.12 per share. 102,375
05/17/2022 Andrew J. Murphy
EVP Research
180   Disposition at $668.68 per share. 120,362
05/17/2022 Andrew J. Murphy
EVP Research
154   Disposition at $667.49 per share. 102,793
05/17/2022 Andrew J. Murphy
EVP Research
352   Disposition at $666.23 per share. 234,512
05/17/2022 Andrew J. Murphy
EVP Research
126   Disposition at $665.36 per share. 83,835
05/17/2022 Andrew J. Murphy
EVP Research
428   Disposition at $664.32 per share. 284,328
05/17/2022 Andrew J. Murphy
EVP Research
472   Disposition at $663.6 per share. 313,219
05/17/2022 Andrew J. Murphy
EVP Research
779   Disposition at $662.57 per share. 516,142
05/17/2022 Andrew J. Murphy
EVP Research
465   Disposition at $661.46 per share. 307,578
05/17/2022 Andrew J. Murphy
EVP Research
77   Disposition at $660.32 per share. 50,844
05/17/2022 Andrew J. Murphy
EVP Research
123   Disposition at $658.56 per share. 81,002
05/17/2022 Andrew J. Murphy
EVP Research
60   Disposition at $657.51 per share. 39,450
05/17/2022 Andrew J. Murphy
EVP Research
58   Disposition at $656.52 per share. 38,078
05/17/2022 Andrew J. Murphy
EVP Research
59   Disposition at $655.4 per share. 38,668
05/16/2022 Andrew J. Murphy
EVP Research
6,457   Derivative/Non-derivative trans. at $648.31 per share. 4,186,137
05/16/2022 Andrew J. Murphy
EVP Research
10,000   Derivative/Non-derivative trans. at $179.13 per share. 1,791,300
05/02/2022 Arthur Frederick Ryan
Director
3   Disposition at $658.09 per share. 1,974
05/02/2022 Arthur Frederick Ryan
Director
3   Disposition at $656.97 per share. 1,970
05/02/2022 Arthur Frederick Ryan
Director
6   Disposition at $655.44 per share. 3,932
05/02/2022 Arthur Frederick Ryan
Director
1   Disposition at $654.21 per share. 654
05/02/2022 Arthur Frederick Ryan
Director
21   Disposition at $653.57 per share. 13,724
05/02/2022 Arthur Frederick Ryan
Director
14   Disposition at $652.71 per share. 9,137
05/02/2022 Arthur Frederick Ryan
Director
10   Disposition at $651.46 per share. 6,514
05/02/2022 Arthur Frederick Ryan
Director
6   Disposition at $650.47 per share. 3,902
05/02/2022 Arthur Frederick Ryan
Director
5   Disposition at $649.62 per share. 3,248
05/02/2022 Arthur Frederick Ryan
Director
4   Disposition at $648.68 per share. 2,594
05/02/2022 Arthur Frederick Ryan
Director
3   Disposition at $647.09 per share. 1,941
05/02/2022 Arthur Frederick Ryan
Director
7   Disposition at $646.49 per share. 4,525
05/02/2022 Arthur Frederick Ryan
Director
3   Disposition at $645.64 per share. 1,936
05/02/2022 Arthur Frederick Ryan
Director
9   Disposition at $644.54 per share. 5,800
05/02/2022 Arthur Frederick Ryan
Director
5   Disposition at $643.76 per share. 3,218
05/02/2022 Marion McCourt
EVP Commercial
1,100   Disposition at $656.97 per share. 722,667
05/02/2022 Marion McCourt
EVP Commercial
1,100   Derivative/Non-derivative trans. at $342.93 per share. 377,223
04/11/2022 Robert E. Landry
EVP Finance CFO
68   Disposition at $738.63 per share. 50,226
04/11/2022 Robert E. Landry
EVP Finance CFO
22   Disposition at $737.89 per share. 16,233
04/11/2022 Robert E. Landry
EVP Finance CFO
189   Disposition at $736.61 per share. 139,219
04/11/2022 Robert E. Landry
EVP Finance CFO
149   Disposition at $735.36 per share. 109,568
04/11/2022 Robert E. Landry
EVP Finance CFO
75   Disposition at $734.53 per share. 55,089
04/11/2022 Robert E. Landry
EVP Finance CFO
1,226   Disposition at $733.52 per share. 899,295
04/11/2022 Robert E. Landry
EVP Finance CFO
22   Disposition at $732.56 per share. 16,116
04/11/2022 Robert E. Landry
EVP Finance CFO
37   Disposition at $731.6 per share. 27,069
04/11/2022 Robert E. Landry
EVP Finance CFO
74   Disposition at $729.76 per share. 54,002
04/08/2022 Christopher Robert Fenimore
SVP Controller
3,451   Derivative/Non-derivative trans. at $736.21 per share. 2,540,660
04/08/2022 Christopher Robert Fenimore
SVP Controller
2,155   Derivative/Non-derivative trans. at $736.21 per share. 1,586,532
04/08/2022 Robert E. Landry
EVP Finance CFO
1,552   Derivative/Non-derivative trans. at $736.21 per share. 1,142,597
04/08/2022 Robert E. Landry
EVP Finance CFO
4,586   Derivative/Non-derivative trans. at $736.21 per share. 3,376,259
04/08/2022 Robert E. Landry
EVP Finance CFO
31   Disposition at $745.27 per share. 23,103
04/08/2022 Robert E. Landry
EVP Finance CFO
56   Disposition at $744.52 per share. 41,693
04/08/2022 Robert E. Landry
EVP Finance CFO
32   Disposition at $743.71 per share. 23,798
04/08/2022 Robert E. Landry
EVP Finance CFO
28   Disposition at $740.98 per share. 20,747
04/08/2022 Robert E. Landry
EVP Finance CFO
29   Disposition at $739.02 per share. 21,431
04/08/2022 Robert E. Landry
EVP Finance CFO
43   Disposition at $735.12 per share. 31,610
04/08/2022 Robert E. Landry
EVP Finance CFO
44   Disposition at $733.38 per share. 32,268
04/08/2022 Robert E. Landry
EVP Finance CFO
16   Disposition at $729.67 per share. 11,674
04/08/2022 Robert E. Landry
EVP Finance CFO
30   Disposition at $728.77 per share. 21,863
04/08/2022 Robert E. Landry
EVP Finance CFO
16   Disposition at $724.33 per share. 11,589
04/08/2022 Christopher Robert Fenimore
SVP Controller
5,000   Derivative/Non-derivative trans. at $270.43 per share. 1,352,150
04/08/2022 Christopher Robert Fenimore
SVP Controller
2,450   Derivative/Non-derivative trans. at $555.67 per share. 1,361,391
04/08/2022 Robert E. Landry
EVP Finance CFO
2,000   Derivative/Non-derivative trans. at $399.66 per share. 799,320
04/08/2022 Robert E. Landry
EVP Finance CFO
6,000   Derivative/Non-derivative trans. at $381.92 per share. 2,291,520
04/07/2022 Robert E. Landry
EVP Finance CFO
1,175   Derivative/Non-derivative trans. at $716.09 per share. 841,405
04/07/2022 Joseph J. LaRosa
EVP General Counsel and Secret
5,114   Disposition at $721.1 per share. 3,687,705
04/07/2022 Bonnie L. Bassler
Director
1,240   Disposition at $725 per share. 899,000
04/07/2022 Robert E. Landry
EVP Finance CFO
1,500   Derivative/Non-derivative trans. at $399.66 per share. 599,490
04/07/2022 Bonnie L. Bassler
Director
1,240   Derivative/Non-derivative trans. at $380.95 per share. 472,378
04/06/2022 Leonard S. Schleifer
President & CEO; Director
2,653   Disposition at $710.04 per share. 1,883,736
04/05/2022 Leonard S. Schleifer
President & CEO; Director
4,461   Disposition at $710.05 per share. 3,167,533
04/01/2022 Robert E. Landry
EVP Finance CFO
15   Disposition at $701.98 per share. 10,529
04/01/2022 Robert E. Landry
EVP Finance CFO
301   Disposition at $695.5 per share. 209,345
04/01/2022 Arthur Frederick Ryan
Director
3   Disposition at $701.82 per share. 2,105
04/01/2022 Arthur Frederick Ryan
Director
4   Disposition at $698.14 per share. 2,792
04/01/2022 Arthur Frederick Ryan
Director
7   Disposition at $697.39 per share. 4,881
04/01/2022 Arthur Frederick Ryan
Director
8   Disposition at $696.5 per share. 5,572
04/01/2022 Arthur Frederick Ryan
Director
14   Disposition at $695.46 per share. 9,736
04/01/2022 Arthur Frederick Ryan
Director
4   Disposition at $694.74 per share. 2,778
04/01/2022 Arthur Frederick Ryan
Director
4   Disposition at $693.69 per share. 2,774
04/01/2022 Arthur Frederick Ryan
Director
10   Disposition at $692.41 per share. 6,924
04/01/2022 Arthur Frederick Ryan
Director
10   Disposition at $691.34 per share. 6,913
04/01/2022 Arthur Frederick Ryan
Director
12   Disposition at $690.59 per share. 8,287
04/01/2022 Arthur Frederick Ryan
Director
3   Disposition at $689.42 per share. 2,068
04/01/2022 Arthur Frederick Ryan
Director
12   Disposition at $688.59 per share. 8,263
04/01/2022 Arthur Frederick Ryan
Director
3   Disposition at $687.45 per share. 2,062
04/01/2022 Arthur Frederick Ryan
Director
6   Disposition at $686.83 per share. 4,120
04/01/2022 Marion McCourt
EVP Commercial
1,000   Disposition at $701.82 per share. 701,820
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
15   Disposition at $701.82 per share. 10,527
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
124   Disposition at $698.26 per share. 86,584
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
64   Disposition at $697.35 per share. 44,630
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
254   Disposition at $696.54 per share. 176,921
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
305   Disposition at $695.36 per share. 212,084
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
259   Disposition at $694.56 per share. 179,891
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
567   Disposition at $693.92 per share. 393,452
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
195   Disposition at $692.54 per share. 135,045
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
641   Disposition at $691.44 per share. 443,213
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
250   Disposition at $690.51 per share. 172,627
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
218   Disposition at $689.43 per share. 150,295
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
799   Disposition at $688.59 per share. 550,183
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
497   Disposition at $687.41 per share. 341,642
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
557   Disposition at $686.26 per share. 382,246
04/01/2022 Joseph J. LaRosa
EVP General Counsel and Secret
369   Disposition at $685.71 per share. 253,026
04/01/2022 Marion McCourt
EVP Commercial
1,000   Derivative/Non-derivative trans. at $342.93 per share. 342,930
03/31/2022 Leonard S. Schleifer
President & CEO; Director
2,886   Disposition at $710.01 per share. 2,049,088
03/31/2022 Christopher Robert Fenimore
SVP Controller
6,857   Derivative/Non-derivative trans. at $700.99 per share. 4,806,688
03/31/2022 Christopher Robert Fenimore
SVP Controller
1,797   Derivative/Non-derivative trans. at $700.99 per share. 1,259,679
03/31/2022 Robert E. Landry
EVP Finance CFO
1,184   Derivative/Non-derivative trans. at $700.99 per share. 829,972
03/31/2022 Christopher Robert Fenimore
SVP Controller
10,000   Derivative/Non-derivative trans. at $270.43 per share. 2,704,300
03/31/2022 Christopher Robert Fenimore
SVP Controller
2,000   Derivative/Non-derivative trans. at $555.67 per share. 1,111,340
03/31/2022 Robert E. Landry
EVP Finance CFO
1,500   Derivative/Non-derivative trans. at $399.66 per share. 599,490
/news/latest/company/us/regn

MarketWatch News on REGN

  1. Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market

    5:18 p.m. Today

    - MarketWatch Automation

  2. Sanofi Receives Another Approval for Blockbuster Drug Dupixent

    5:38 p.m. May 20, 2022

    - Barron's Online

  3. Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market

    5:17 p.m. May 20, 2022

    - MarketWatch Automation

  4. Regeneron Pharmaceuticals Inc. stock rises Monday, outperforms market

    5:17 p.m. May 16, 2022

    - MarketWatch Automation

  5. Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market

    5:18 p.m. May 9, 2022

    - MarketWatch Automation

  6. Regeneron First-Quarter Earnings Top Forecasts

    11:23 a.m. May 4, 2022

    - Barron's Online

  7. Loading more headlines...
/news/nonmarketwatch/company/us/regn

Other News on REGN

  1. Why Regeneron Investors Shouldn't Fear Its Patent Cliff

    7:42 a.m. Today

    - Motley Fool

  2. Regeneron's (REGN) Evkeeza Positive in Late-Stage Study

    12:26 p.m. May 23, 2022

    - Zacks.com

  3. Regeneron: Bright Future Ahead

    3:55 a.m. May 23, 2022

    - Seeking Alpha

  4. Galapagos: Can The Company Turn Around?

    1:18 p.m. May 19, 2022

    - Seeking Alpha

  5. PUTNAM INVESTMENTS LLC Buys 1, Sells 4 in 1st Quarter

    1:00 p.m. May 18, 2022

    - GuruFocus.com

  6. The Correction In Biopharmaceutical Stocks Is Likely Over

    12:51 a.m. May 18, 2022

    - Seeking Alpha

  7. My 'Do Nothing Club' Returned 68% in the Past Year

    9:35 a.m. May 16, 2022

    - GuruFocus.com

  8. Top 5 1st Quarter Trades of Dodge & Cox

    5:00 p.m. May 13, 2022

    - GuruFocus.com

  9. Loading more headlines...

At a Glance

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591-6707

Phone

1 9148477000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$16.07B

Net Income

$8.08B

Employees

10,368

/news/pressrelease/company/us/regn

Press Releases on REGN

  1. Regeneron Pharmaceuticals REGN Pivots Trading Plans and Risk Controls

    2:52 a.m. May 20, 2022

    - Stock Traders Daily

  2. When Regeneron Pharmaceuticals (REGN) Moves Investors should Listen

    9:28 a.m. May 10, 2022

    - Stock Traders Daily

  3. Regeneron Announces Investor Conference Presentations

    4:15 p.m. May 2, 2022

    - PR Newswire - PRF

  4. Trend Tracker for Regeneron Pharmaceuticals REGN

    5:23 p.m. April 30, 2022

    - Stock Traders Daily

  5. Regeneron Pharmaceuticals REGN Trading Signals

    12:44 a.m. April 21, 2022

    - Stock Traders Daily

  6. Loading more headlines...
Link to MarketWatch's Slice.